ROIV - Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today? | Benzinga
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG) in initial data from a Phase 1 trial in healthy adults, with no dose-related changes in serum albumin or LDL-C.
"These first-in-human results are consistent with those observed in prior non-human primate studies, and we look forward to sharing additional MAD data in November," said Pete ...